title: Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
abstract: BACKGROUND
  To determine the feasibility of two chemotherapy regimens in elderly patients with advanced ovarian carcinoma (AOC).
  
  
  METHODS
  Eighty-three patients >or=70 years were previously enrolled in a trial evaluating carboplatin and cyclophosphamide (CC). On the basis of identical eligibility criteria, 75 further patients were enrolled in a trial evaluating carboplatin and paclitaxel (Taxol) (CP). The primary end point of these studies was the feasibility of six courses of chemotherapy. Comprehensive geriatric assessment (CGA) parameters were assessed in terms of prognostic factors.
  
  
  RESULTS
  More patients in the CC group presented with performance status of two or more, depression symptoms, use of co-medications, hypoalbuminemia, abnormal Mini-Mental Status score, or sub-optimal surgery. Both regimens appeared feasible: 75.6% in the CC group and 68.1% in the CP group completed six courses. CC and CP groups had similar overall survival (OS). Independent prognostic factors of poorer OS were the following: increasing age (P = 0.013), depression symptoms at baseline (P < 0.001), International Federation of Gynecology and Obstetrics stage IV (P = 0.001), and use of paclitaxel (P = 0.025).
  
  
  CONCLUSIONS
  As this is a non-randomised retrospective review of two consecutive studies, no firm conclusion can be drawn. It seems, however, that in elderly patients with AOC the use of paclitaxel results in more toxicity. CGA parameters and particularly emotional disorders might help to determine a priori the risk/benefit ratio of chemotherapy in this patient population.
authors.affiliation: Medical Oncology Department, Hospices Civils de Lyon et Université de Lyon, France.
authors.forename: O
authors.initials: O
authors.lastname: Trédan
authors.forename: J-F
authors.initials: JF
authors.lastname: Geay
authors.forename: S
authors.initials: S
authors.lastname: Touzet
authors.forename: R
authors.initials: R
authors.lastname: Delva
authors.forename: B
authors.initials: B
authors.lastname: Weber
authors.forename: J
authors.initials: J
authors.lastname: Cretin
authors.forename: J
authors.initials: J
authors.lastname: Provencal
authors.forename: J
authors.initials: J
authors.lastname: Martin
authors.forename: L
authors.initials: L
authors.lastname: Stefani
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.forename: G
authors.initials: G
authors.lastname: Freyer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D005240:Feasibility Studies; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D011446:Prospective Studies; D019233:Retreatment; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel